B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines

Andrew D. Zelenetz; Leo I. Gordon; Jeremy S. Abramson; Ranjana H. Advani; Nancy L. Bartlett; Paolo F. Caimi; Julie E. Chang; Julio C. Chavez; Beth Christian; Luis E. Fayad; Martha J. Glenn; Thomas M. Habermann; Nancy Lee Harris; Francisco Hernandez-Ilizaliturri; Mark S. Kaminski; Christopher R. Kelsey; Nadia Khan; Susan Krivacic; Ann S. LaCasce; Amitkumar Mehta; Auayporn Nademanee; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Kenneth B. Roberts; Stephen D. Smith; Erin D. Snyder; Lode J. Swinnen; Julie M. VoseA; Mary A. Dwyer; Hema Sundar

doi:10.6004/jnccn.2019.0029

B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines

Andrew D. Zelenetz
, Leo I. Gordon
, Jeremy S. Abramson
, Ranjana H. Advani
, Nancy L. Bartlett
, Paolo F. Caimi
, Julie E. Chang
, Julio C. Chavez
, Beth Christian
, Luis E. Fayad
, Martha J. Glenn
, Thomas M. Habermann
, Nancy Lee Harris
, Francisco Hernandez-Ilizaliturri
, Mark S. Kaminski
, Christopher R. Kelsey
, Nadia Khan
, Susan Krivacic
, Ann S. LaCasce
, Amitkumar Mehta

Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. VoseA, Mary A. Dwyer, Hema Sundar

Research output: Contribution to journal › Article › peer-review

145 Scopus citations

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Original language	English
Pages (from-to)	650-661
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	6
DOIs	https://doi.org/10.6004/jnccn.2019.0029
State	Published - 2019

Access to Document

10.6004/jnccn.2019.0029

Cite this

Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., Chang, J. E., Chavez, J. C., Christian, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Harris, N. L., Hernandez-Ilizaliturri, F., Kaminski, M. S., Kelsey, C. R., Khan, N., Krivacic, S., LaCasce, A. S., ... Sundar, H. (2019). B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 17(6), 650-661. https://doi.org/10.6004/jnccn.2019.0029

@article{e8a70a7528044edaa8799ef94867adb1,

title = "B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines",

abstract = "Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15\% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.",

author = "Zelenetz, \{Andrew D.\} and Gordon, \{Leo I.\} and Abramson, \{Jeremy S.\} and Advani, \{Ranjana H.\} and Bartlett, \{Nancy L.\} and Caimi, \{Paolo F.\} and Chang, \{Julie E.\} and Chavez, \{Julio C.\} and Beth Christian and Fayad, \{Luis E.\} and Glenn, \{Martha J.\} and Habermann, \{Thomas M.\} and Harris, \{Nancy Lee\} and Francisco Hernandez-Ilizaliturri and Kaminski, \{Mark S.\} and Kelsey, \{Christopher R.\} and Nadia Khan and Susan Krivacic and LaCasce, \{Ann S.\} and Amitkumar Mehta and Auayporn Nademanee and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Roberts, \{Kenneth B.\} and Smith, \{Stephen D.\} and Snyder, \{Erin D.\} and Swinnen, \{Lode J.\} and VoseA, \{Julie M.\} and Dwyer, \{Mary A.\} and Hema Sundar",

year = "2019",

doi = "10.6004/jnccn.2019.0029",

language = "English",

volume = "17",

pages = "650--661",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "6",

}

Zelenetz, AD, Gordon, LI, Abramson, JS, Advani, RH, Bartlett, NL, Caimi, PF, Chang, JE, Chavez, JC, Christian, B, Fayad, LE, Glenn, MJ, Habermann, TM, Harris, NL, Hernandez-Ilizaliturri, F, Kaminski, MS, Kelsey, CR, Khan, N, Krivacic, S, LaCasce, AS, Mehta, A, Nademanee, A, Rabinovitch, R, Reddy, N, Reid, E, Roberts, KB, Smith, SD, Snyder, ED, Swinnen, LJ, VoseA, JM, Dwyer, MA & Sundar, H 2019, 'B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 6, pp. 650-661. https://doi.org/10.6004/jnccn.2019.0029

TY - JOUR

T1 - B-cell lymphomas, version 3.2019

T2 - Featured updates to the NCCN Guidelines

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Bartlett, Nancy L.

AU - Caimi, Paolo F.

AU - Chang, Julie E.

AU - Chavez, Julio C.

AU - Christian, Beth

AU - Fayad, Luis E.

AU - Glenn, Martha J.

AU - Habermann, Thomas M.

AU - Harris, Nancy Lee

AU - Hernandez-Ilizaliturri, Francisco

AU - Kaminski, Mark S.

AU - Kelsey, Christopher R.

AU - Khan, Nadia

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Mehta, Amitkumar

AU - Nademanee, Auayporn

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Roberts, Kenneth B.

AU - Smith, Stephen D.

AU - Snyder, Erin D.

AU - Swinnen, Lode J.

AU - VoseA, Julie M.

AU - Dwyer, Mary A.

AU - Sundar, Hema

PY - 2019

Y1 - 2019

N2 - Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

AB - Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

UR - https://www.scopus.com/pages/publications/85068138478

U2 - 10.6004/jnccn.2019.0029

DO - 10.6004/jnccn.2019.0029

M3 - Article

C2 - 31200358

AN - SCOPUS:85068138478

SN - 1540-1405

VL - 17

SP - 650

EP - 661

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 6

ER -

B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this